Clinical Trial Update: A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) [Phase 3]

View source ↗

Summary

An update on the Phase 3 DESTINY-Breast05 trial comparing trastuzumab deruxtecan (Enhertu) with trastuzumab emtansine (Kadcyla) in high-risk HER2-positive breas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• Kadcyla (ado-trastuzumab emtansine)

Snippet

Sponsor: Daiichi Sankyo | Conditions: HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING